The Clorox Company $CLX Shares Bought by Coston McIsaac & Partners

Coston McIsaac & Partners raised its stake in The Clorox Company (NYSE:CLX) by 17.8% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 35,601 shares of the company’s stock after buying an additional 5,379 shares during the quarter. Coston McIsaac & Partners’ holdings in Clorox were worth $3,689,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Vermillion & White Wealth Management Group LLC acquired a new stake in Clorox during the third quarter worth about $25,000. Caitlin John LLC boosted its holdings in Clorox by 1,807.1% in the 4th quarter. Caitlin John LLC now owns 267 shares of the company’s stock valued at $27,000 after purchasing an additional 253 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in Clorox in the 2nd quarter valued at about $29,000. Vision Financial Markets LLC grew its stake in shares of Clorox by 166.7% in the 4th quarter. Vision Financial Markets LLC now owns 320 shares of the company’s stock valued at $32,000 after buying an additional 200 shares during the period. Finally, SHP Wealth Management purchased a new stake in shares of Clorox in the 4th quarter valued at approximately $35,000. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Trading Down 0.0%

Shares of NYSE CLX opened at $97.51 on Monday. The company has a current ratio of 0.84, a quick ratio of 0.65 and a debt-to-equity ratio of 27.03. The stock has a market capitalization of $11.79 billion, a PE ratio of 15.83, a PEG ratio of 0.51 and a beta of 0.56. The Clorox Company has a twelve month low of $84.70 and a twelve month high of $132.03. The stock has a fifty day simple moving average of $94.67 and a 200-day simple moving average of $104.45.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Thursday, April 30th. The company reported $1.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.55 by $0.09. The company had revenue of $1.67 billion for the quarter, compared to analyst estimates of $1.67 billion. Clorox had a net margin of 11.18% and a return on equity of 443.64%. The business’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.45 earnings per share. Clorox has set its FY 2026 guidance at 5.450-5.650 EPS. On average, equities analysts forecast that The Clorox Company will post 5.61 earnings per share for the current year.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were purchased at an average cost of $85.82 per share, with a total value of $429,100.00. Following the purchase, the director directly owned 18,000 shares in the company, valued at approximately $1,544,760. This represents a 38.46% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.63% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CLX. Morgan Stanley reduced their price target on shares of Clorox from $110.00 to $97.00 and set an “equal weight” rating on the stock in a research report on Friday, May 1st. Evercore reiterated an “underperform” rating and issued a $110.00 price objective on shares of Clorox in a research report on Friday, May 1st. Jefferies Financial Group cut their target price on Clorox from $139.00 to $125.00 and set a “buy” rating for the company in a research note on Monday, May 4th. JPMorgan Chase & Co. reduced their target price on Clorox from $99.00 to $95.00 and set an “underweight” rating on the stock in a research report on Friday, May 1st. Finally, Barclays decreased their price target on Clorox from $102.00 to $85.00 and set an “underweight” rating on the stock in a research note on Friday, May 1st. One analyst has rated the stock with a Buy rating, eleven have given a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Clorox presently has an average rating of “Reduce” and a consensus target price of $103.40.

Clorox Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.